Hikma Pharmaceuticals Share News (HIK)

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

Sector movers: Shire and AZN lead pharma stocks lower on M&A risk

The pharmaceutical sector dropped on Wednesday on the back of fears about risks to mergers and acquisitions (M&A) activity, with Shire sinking sharply. Concerns that stricter rules on so-called 'tax inversion' in the US could scupper Abbvie's £32bn takeover of London-listed Shire dented the latter'

Friday broker round-up UPDATE

AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation. Avacta: Numis places both its target price and its buy recommendation under review. Barclays: Berenberg upgrades from sell to hold with a target price of 220p. Bodycote: UBS shifts target price f

Hikma to purchase Ben Venue manufacturing site

Hikma Pharmaceuticals confirmed its acquisition of the generic injectables manufacturing site owned by US group Ben Venue Laboratories. The deal, which follows an exclusivity arrangement inked in May, will form part of the previously announcement agreement to acquire Ben Venue Laboratories for $22

Hikma Pharmaceuticals To Acquire Manufacturing Site From Ben Venue

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

BUZZ-European pharma: 7-year high P/E in focus as M&A fervour pauses

** A pause in the heady stream of M&A headlines around the European healthcare sector & earnings season shines the spotlight on 7-year high valuations. ** Deal-making and the popularity of defensives have made sector a big draw for investors this year second only to utilities. http://link.r

UK WINNERS & LOSERS: Shire Gains As Takeover By AbbVie Confirmed

UK BROKER RATINGS: Exane BNP Upgrades Burberry To Outperform

Friday broker round-up UPDATE

Barclays: Credit Suisse cuts target price from 275p to 235p retaining a neutral rating. Barratt Developments: Liberum Capital reduces target price from 468p to 387p and downgrades to hold. Bellway: Liberum Capital reduces target price from 1900p to 1764p, while leaving its buy recommendation uncha

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Thursday broker round-up UPDATE

Antofagasta: Canaccord Genuity cuts target price from 870p to 835p and maintains a hold recommendation. African Minerals: Canaccord Genuity reduces target price from 230p to 170p and keeps a buy recommendation. Ashmore Group: Goldman Sachs downgrades to neutral with a target price of 430p. Barcla